Korean J Gastroenterol.  2023 May;81(5):230-232. 10.4166/kjg.2023.047.

Safety of Biologic Therapy in Older Adults with Inflammatory Bowel Diseases

• Gweon TG

• KMID: 2542791
• DOI: http://doi.org/10.4166/kjg.2023.047

Reference

1. Cheng D, Kochar B, Cai T, Ritchie CS, Ananthakrishnan AN. 2022; Comorbidity influences the comparative safety of biologic therapy in older adults with inflammatory bowel diseases. Am J Gastroenterol. 117:1845–1850. DOI: 10.14309/ajg.0000000000001907. PMID: 35854436.

2. Korean Association for the Study of Intestinal Diseases. 2020 Inflammatory bowel disease fact sheet in Korea [Internet]. Seoul: Korean Association for the Study of Intestinal Diseases;2020. cited 2023 Apr 11. Available from: http://m.kasid.org/file/IBM/IBD%20fact%20sheet_1217.pdf.

3. Hong SW, Ye BD, Cheon JH, et al. 2022; Clinical features and long-term prognosis of crohn's disease in Korea: Results from the prospective CONNECT study. Gut Liver. 16:907–920. DOI: 10.5009/gnl210299. PMID: 35321956. PMCID: PMC9668509.

4. Na SY, Choi CH, Song EM, et al. IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intest Res. 2023; 21:61–87. DOI: 10.5217/ir.2022.00007. PMID: 35645321. PMCID: PMC9911265.

5. Koh SJ, Hong SN, Park SK, et al. IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease. Intest Res. 2023; 21:43–60. DOI: 10.5217/ir.2022.00029. PMID: 36245343. PMCID: PMC9911268.

6. Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. 2021; AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 160:2512–2556.e9. DOI: 10.1053/j.gastro.2021.04.023. PMID: 34051985. PMCID: PMC8986997.

7. Solitano V, Facciorusso A, Jess T, et al. 2023; Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 21:907–921.e2. DOI: 10.1016/j.cgh.2022.07.032. PMID: 35944832.